[{"orgOrder":0,"company":"Forbius","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"AVID200","moa":"TGF beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"Forbius","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Forbius \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Forbius \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Forbius","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"AVID200","moa":"TGF beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"Forbius","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Forbius \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Forbius \/ Bristol Myers Squibb"}]

Find Clinical Drug Pipeline Developments & Deals by Forbius

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Pursuant to the terms of the transaction, Forbius’ non-TGF-beta assets were transferred to a newly formed private company which is being retained by Forbius’ existing shareholders.

                          Brand Name : AVID200

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          September 21, 2020

                          Lead Product(s) : AVID200

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Bristol Myers Squibb

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under this transaction, Bristol Myers Squibb would acquire Forbius’s TGF-beta program, including the program’s lead investigational asset, AVID200. TGF-beta is a key cytokine that regulates various cell processes, including regulation of the immune s...

                          Brand Name : AVID200

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          August 24, 2020

                          Lead Product(s) : AVID200

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Bristol Myers Squibb

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank